argenx
ISIN US04016X1019
|WKN A2H9WD
Overview
Description
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Healthcare Biopharmaceuticals Other Biopharmaceuticals Netherlands
Financials
Key metrics
| Market capitalisation, EUR | 33,029.65 m |
| EPS, EUR | - |
| P/B ratio | 6.27 |
| P/E ratio | 40.82 |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 2,021.24 m |
| Net income, EUR | 768.76 m |
| Profit margin | 38.03% |
What ETF is argenx in?
There are 23 ETFs which contain argenx. All of these ETFs are listed in the table below. The ETF with the largest weighting of argenx is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
